Document ID: FDA-2014-N-0189-4671
Agency: fda
Document Type: Supporting & Related Material
Title: 
Posted Date: 2014-06-15T04:00Z

Comment Info: =================

General Comment:Dear Mr. Zeller:

As a consumer I hereby request an extension to the comment period for the Food and Drug Administration's  Proposed Rule Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking and Prevention and Tobacco Control Act published at 79 Fed. Reg. 23,142 and Federal Register No. 2014-09491. On behalf of myself, I am requesting that the comment period for the Proposed Rule be extended by the FDA for an additional 105 days, from its current 75-day period, to 180 days.  I have many points of interest to discuss and I need more time to fully support my facts as I see them.

The Proposed Rule raises far too many significant issues and questions that are important and relevant to me, as a consumer of products that are proposed for regulation. The Proposed Rule asks about a hundred different questions I want to respond to. I want to provide my thoughts and comments on many of these issues, but my time to devote to researching and providing thoughtful comments on these important questions is limited. I have already spent many hours researching and studying these issues, but I need more time.  I know the FDA has spent years working on these regulations but I feel like us consumers deserve enough time to prove to you that these regulations do nothing to help or protect the individual or the general public's health, and that is what the FDA is supposed to do right?   This is our only opportunity, as consumers, to provide our feedback and to keep our governments power in check.

I feel very strongly about e-cigarettes as a replacement to combustible cigarettes. Quite simply,THEY SAVED MY LIFE!  I wish to provide you with my personal story, as well as science- and evidence-based responses to your questions so that you can take my comment into account. I realize that the FDA has the authority under 21 CFR 10.40 to extend this time frame and that the FDA has exercised this authority on numerous occasions in the past. I would therefore ask that you do so here, so that all stakeholders have the opportunity to provide their comments and concerns on this proposed regulation.

I appreciate your consideration of my request and am happy to discuss this issue with you further.